Chern‐En Chiang
YOU?
Author Swipe
View article: Bibliographic analysis of Taiwanese publications in the Web of Science Respiratory System Category from 1972 to 2023
Bibliographic analysis of Taiwanese publications in the Web of Science Respiratory System Category from 1972 to 2023 Open
Background: Academic publications are important for developing medical specialties. Respiratory system diseases are among the most common human diseases and have a significant impact on morbidity and mortality. This is particularly true re…
View article: Impact of PIK3CA Mutations on the Clinical Benefits of CDK 4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer: An Updated Pairwise and Network Meta-Analysis
Impact of PIK3CA Mutations on the Clinical Benefits of CDK 4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer: An Updated Pairwise and Network Meta-Analysis Open
Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have revolutionized the treatment of hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer. However, identif…
View article: Risk factors and reasons for romosozumab nonadherence in a case-control study
Risk factors and reasons for romosozumab nonadherence in a case-control study Open
Risk factors and reasons for romosozumab nonadherence remain unclear. This study compared patients who adhered to romosozumab therapy with those who did not to identify possible risk factors and reasons for treatment nonadherence. This cas…
View article: Finerenone According to Frailty in Heart Failure
Finerenone According to Frailty in Heart Failure Open
Importance Patients with frailty are often perceived to have a less favorable benefit-risk profile for novel therapies and therefore may be less likely to receive these. Objective To examine the efficacy and safety of finerenone, compared …
View article: Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global Relevance
Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global Relevance Open
Background The collection of race and ethnicity data in clinical trials using standardized categories is recommended by the US Food and Drug Administration, although this is primarily for domestic reasons. The applicability and understandi…
View article: Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES Open
Contains fulltext : 320894.pdf (Publisher’s version ) (Closed access)
View article: An international modified Delphi consensus study on the optimal diagnosis and treatment of patients with HFpEF
An international modified Delphi consensus study on the optimal diagnosis and treatment of patients with HFpEF Open
The burden of HFpEF is set to increase in the future. The high levels of consensus achieved in this study show that there is willingness to implement change and improve patient outcomes for those with this condition. A series of actionable…
View article: Comparison of machine learning and conventional criteria in detecting left ventricular hypertrophy and prognosis with electrocardiography
Comparison of machine learning and conventional criteria in detecting left ventricular hypertrophy and prognosis with electrocardiography Open
Aims Left ventricular hypertrophy (LVH) is clinically important; current electrocardiography (ECG) diagnostic criteria are inadequate for early detection. This study aimed to develop an artificial intelligence (AI)-based algorithm to impro…
View article: LV Diastolic Dysfunction and Inappropriate LV Filling Pressure Escalation: The Core of Exercise Intolerance in Heart Failure
LV Diastolic Dysfunction and Inappropriate LV Filling Pressure Escalation: The Core of Exercise Intolerance in Heart Failure Open
Among resting and exertional echocardiographic variables, the peak medial E/e' to CO ratio, a non-invasive assessment of exertional left ventricular filling pressure indexed to CO, was the major determinant of exercise capacity in patients…
View article: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction Open
In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo. (…
View article: The impact of LV filling pressure indexed to cardiac output on exercise capacity in HF subjects
The impact of LV filling pressure indexed to cardiac output on exercise capacity in HF subjects Open
Purpose Exercise intolerance is the most common symptom of patients with heart failure (HF), regardless of the phenotypes. We aim to investigate the determinants of exercise capacity in chronic stable HF with reduced, mildly reduced, prese…
View article: ELUCIDATE Trial: A Single‐Center Randomized Controlled Study
ELUCIDATE Trial: A Single‐Center Randomized Controlled Study Open
Background Dapagliflozin, a sodium–glucose cotransporter 2 inhibitor, is an epochal oral antidiabetic drug that improves cardiorenal outcomes. However, the effect of early dapagliflozin intervention on left ventricular (LV) remodeling in p…
View article: Cardiovascular Risk in Patients With Treated Isolated Diastolic Hypertension and Isolated Low Diastolic Blood Pressure
Cardiovascular Risk in Patients With Treated Isolated Diastolic Hypertension and Isolated Low Diastolic Blood Pressure Open
Background The prognosis of high or markedly low diastolic blood pressure (DBP) with normalized on‐treatment systolic blood pressure on major adverse cardiovascular events (MACEs) is uncertain. This study examined whether treated isolated …
View article: TIMP-1 in the prognosis of patients who underwent coronary artery bypass surgery: a 12-year follow-up study
TIMP-1 in the prognosis of patients who underwent coronary artery bypass surgery: a 12-year follow-up study Open
Introduction Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) have been linked to clinical outcomes in patients with coronary artery disease (CAD). However, the prognostic value of TIMP-1 in patients wit…
View article: Effects of Dapagliflozin in Patients in Asia
Effects of Dapagliflozin in Patients in Asia Open
In the global DELIVER trial, dapagliflozin reduced the risk of CV death or worsening HF events and was well tolerated among participants enrolled in both Asia and other geographic regions.
View article: Efficacy and Safety of Inclisiran in Asian Patients
Efficacy and Safety of Inclisiran in Asian Patients Open
View article: Effect of dapagliflozin in patients in Asia with heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER
Effect of dapagliflozin in patients in Asia with heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER Open
Background A large and growing fraction of the global heart failure (HF) population lives in Asia. One-fifth of participants in the DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart F…
View article: Cardiovascular risk in treated hypertensive patients with isolated diastolic hypertension and isolated low diastolic blood pressure
Cardiovascular risk in treated hypertensive patients with isolated diastolic hypertension and isolated low diastolic blood pressure Open
Background The prognosis of high or markedly low diastolic blood pressure (DBP) with normalized on-treatment systolic blood pressure (SBP) on major adverse cardiovascular events (MACE) is uncertain. This study examined whether isolated dia…
View article: 2023 Consensus of Taiwan Society of Cardiology on the Pharmacological Treatment of Chronic Heart Failure.
2023 Consensus of Taiwan Society of Cardiology on the Pharmacological Treatment of Chronic Heart Failure. Open
The prevalence of heart failure is increasing, causing a tremendous burden on health care systems around the world. Although mortality rate of heart failure has been significantly reduced by several effective agents in the past 3 decades, …
View article: Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome
Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome Open
BackgroundMany patients require revascularization after index acute coronary syndrome (ACS). Lipoprotein(a) is thought to play a pathogenic role in atherothrombosis. In ODYSSEY OUTCOMES, alirocumab reduced major adverse cardiovascular even…
View article: 2023 Guidelines of the Taiwan Society of Cardiology on the Diagnosis and Management of Chronic Coronary Syndrome.
2023 Guidelines of the Taiwan Society of Cardiology on the Diagnosis and Management of Chronic Coronary Syndrome. Open
Coronary artery disease (CAD) covers a wide spectrum from persons who are asymptomatic to those presenting with acute coronary syndromes (ACS) and sudden cardiac death. Coronary atherosclerotic disease is a chronic, progressive process tha…
View article: Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases Open
Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly common liver disease worldwide. MAFLD is diagnosed based on the presence of steatosis on images, histological findings, or serum marker levels as well as the p…
View article: Optimal stroke preventive strategy for patients aged 80 years or older with atrial fibrillation: a systematic review with traditional and network meta-analysis
Optimal stroke preventive strategy for patients aged 80 years or older with atrial fibrillation: a systematic review with traditional and network meta-analysis Open
Background An optimal antithrombotic strategy for patients aged 80 years or older with atrial fibrillation (AF) remains elusive. Objective Using a systematic review with traditional and network meta-analysis, we investigated outcomes in AF…
View article: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial Open
With modern treatments for heart failure with reduced ejection fraction (EF), indicative of impaired cardiac systolic function, patients may exhibit an increase in EF. Limited data are available regarding the clinical management of this gr…
View article: Effectiveness of salt substitute on cardiovascular outcomes: A systematic review and meta‐analysis
Effectiveness of salt substitute on cardiovascular outcomes: A systematic review and meta‐analysis Open
Hypertension‐related death is the leading cause of mortality worldwide, making blood pressure (BP) control an important issue. Salt substitute is a non‐pharmaceutical strategy to improve hypertension control. The goal of this study was to …
View article: Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab Open
Background: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB levels and apoB lowering hold incremental predictive information on residual risk after acute coronary syndrome beyond that provided by lo…
View article: Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial
Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial Open
Background: Frailty is increasing in prevalence. Because patients with frailty are often perceived to have a less favorable risk/benefit profile, they may be less likely to receive new pharmacologic treatments. We investigated the efficacy…
View article: Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction Open
Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction. (Funded by AstraZeneca; DELIVER ClinicalTrials.gov number, NC…
View article: Stroke Prevention in Atrial Fibrillation
Stroke Prevention in Atrial Fibrillation Open
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated with substantial increases in the risk for stroke and systemic thromboembolism. With the successful introduction of the first non-vitamin K antagoni…
View article: Stroke Prevention in Atrial Fibrillation
Stroke Prevention in Atrial Fibrillation Open